Denali Therapeutics Inc. (NASDAQ: DNLI) is a Healthcare company (Biotechnology) with a market capitalization of $2.9B. The Maz Rating grades it against the other companies in its sector.
Denali Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $18.00, Denali Therapeutics Inc. trades at 133.5x sales and 3.6x book value. Over the last twelve months it generated about $22M of revenue and a net loss of $280M. It runs a gross margin of 72.0%, an operating margin of -2488.1% and a net margin of -1470.5%. It shows return on equity of -34.0%, return on invested capital of -45.4% and a free cash flow yield of -15.7%. On the balance sheet: a debt-to-equity ratio of 0.26 and a current ratio of 6.21. Over the past 52 weeks the share price ranged from $15.34 to $27.30, with a beta of 1.08.
Denali Therapeutics Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 19 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.